AAPL319.97-8.24 (-2.51%) ▼|ABBV256.46-3.75 (-1.44%) ▼|ABT107.40-0.91 (-0.84%) ▼|ACN180.14-6.56 (-3.51%) ▼|ADBE259.44-7.07 (-2.65%) ▼|AMAT469.15+14.44 (+3.18%) ▲|AMD491.64+14.07 (+2.95%) ▲|AMGN403.23-34.00 (-7.78%) ▼|AMT175.47-0.28 (-0.16%) ▼|AMZN255.62-2.90 (-1.12%) ▼|AVGO366.80+8.91 (+2.49%) ▲|AXP322.83-3.26 (-1.00%) ▼|BA211.71-0.52 (-0.24%) ▼|BAC62.36-0.33 (-0.52%) ▼|BKNG187.95-5.34 (-2.76%) ▼|BLK1,107.63-8.47 (-0.76%) ▼|BMY64.75-2.09 (-3.12%) ▼|BNY163.27-1.58 (-0.96%) ▼|BRK-B501.63-4.27 (-0.84%) ▼|C136.21-1.53 (-1.11%) ▼|CAT820.33+6.47 (+0.80%) ▲|CL88.13-0.63 (-0.71%) ▼|CMCSA26.23-0.27 (-1.00%) ▼|COF216.53-3.02 (-1.38%) ▼|COP136.05+1.76 (+1.31%) ▲|COST911.37-4.38 (-0.48%) ▼|CRM251.78-7.52 (-2.90%) ▼|CSCO109.01-0.19 (-0.17%) ▼|CVS95.50-1.25 (-1.29%) ▼|CVX211.96+3.43 (+1.64%) ▲|DE687.04-6.64 (-0.96%) ▼|DHR205.38-2.24 (-1.08%) ▼|DIS104.81-0.48 (-0.46%) ▼|DUK120.54+0.32 (+0.26%) ▲|EMR152.72-0.08 (-0.05%) ▼|FDX320.49-1.88 (-0.58%) ▼|GD359.99+0.60 (+0.17%) ▲|GE335.79-1.24 (-0.37%) ▼|GEV947.49+5.57 (+0.59%) ▲|GILD146.58-4.42 (-2.92%) ▼|GM87.23-0.51 (-0.58%) ▼|GOOG332.40-2.92 (-0.87%) ▼|GOOGL335.77-2.69 (-0.79%) ▼|GS1,033.62-4.68 (-0.45%) ▼|HD320.32-0.68 (-0.21%) ▼|HON208.32-1.29 (-0.62%) ▼|IBM231.56-3.28 (-1.40%) ▼|INTC101.68+5.88 (+6.14%) ▲|INTU321.32-11.38 (-3.42%) ▼|ISRG358.51-8.19 (-2.23%) ▼|JNJ268.32-6.83 (-2.48%) ▼|JPM357.00-1.62 (-0.45%) ▼|KO88.24+0.17 (+0.19%) ▲|LIN472.33-5.25 (-1.10%) ▼|LLY1,116.00-32.74 (-2.85%) ▼|LMT536.40+11.24 (+2.14%) ▲|LOW204.33-0.24 (-0.12%) ▼|LRCX316.43+8.78 (+2.85%) ▲|MA570.32-8.85 (-1.53%) ▼|MCD255.15-0.57 (-0.22%) ▼|MDLZ61.37+0.09 (+0.15%) ▲|MDT92.35-1.81 (-1.92%) ▼|META617.88+1.11 (+0.18%) ▲|MMM168.03-0.48 (-0.28%) ▼|MO68.94+0.07 (+0.10%) ▲|MRK146.57-3.76 (-2.50%) ▼|MS217.40-0.31 (-0.14%) ▼|MSFT494.03-5.67 (-1.13%) ▼|MU1,016.88+0.29 (+0.03%) ▲|NEE83.64+0.22 (+0.26%) ▲|NFLX76.53-1.73 (-2.20%) ▼|NKE38.47+0.06 (+0.14%) ▲|NOW135.36-5.91 (-4.18%) ▼|NVDA232.54+2.18 (+0.95%) ▲|ORCL169.32+10.49 (+6.60%) ▲|PEP138.17+0.54 (+0.39%) ▲|PFE27.80-0.65 (-2.27%) ▼|PG145.43-1.02 (-0.70%) ▼|PLTR174.60+0.27 (+0.15%) ▲|PM185.36+2.85 (+1.56%) ▲|QCOM179.87+11.13 (+6.59%) ▲|RTX200.79-1.34 (-0.66%) ▼|SBUX104.47-1.35 (-1.28%) ▼|SCHW109.29-1.09 (-0.99%) ▼|SO88.11-0.66 (-0.74%) ▼|SPG209.44-2.08 (-0.98%) ▼|T25.68-0.51 (-1.95%) ▼|TMO606.80-6.95 (-1.13%) ▼|TMUS182.45+0.93 (+0.51%) ▲|TSLA361.55+7.47 (+2.11%) ▲|TXN258.44+4.61 (+1.82%) ▲|UBER75.76-0.20 (-0.26%) ▼|UNH397.14-3.80 (-0.95%) ▼|UNP289.62+0.47 (+0.16%) ▲|UPS102.29-1.21 (-1.17%) ▼|USB63.37-0.16 (-0.25%) ▼|V375.07-3.68 (-0.97%) ▼|VZ50.14-0.45 (-0.89%) ▼|WFC89.97+0.78 (+0.87%) ▲|WMT107.14-1.28 (-1.18%) ▼|XOM159.47-2.74 (-1.69%) ▼|AAPL319.97-8.24 (-2.51%) ▼|ABBV256.46-3.75 (-1.44%) ▼|ABT107.40-0.91 (-0.84%) ▼|ACN180.14-6.56 (-3.51%) ▼|ADBE259.44-7.07 (-2.65%) ▼|AMAT469.15+14.44 (+3.18%) ▲|AMD491.64+14.07 (+2.95%) ▲|AMGN403.23-34.00 (-7.78%) ▼|AMT175.47-0.28 (-0.16%) ▼|AMZN255.62-2.90 (-1.12%) ▼|AVGO366.80+8.91 (+2.49%) ▲|AXP322.83-3.26 (-1.00%) ▼|BA211.71-0.52 (-0.24%) ▼|BAC62.36-0.33 (-0.52%) ▼|BKNG187.95-5.34 (-2.76%) ▼|BLK1,107.63-8.47 (-0.76%) ▼|BMY64.75-2.09 (-3.12%) ▼|BNY163.27-1.58 (-0.96%) ▼|BRK-B501.63-4.27 (-0.84%) ▼|C136.21-1.53 (-1.11%) ▼|CAT820.33+6.47 (+0.80%) ▲|CL88.13-0.63 (-0.71%) ▼|CMCSA26.23-0.27 (-1.00%) ▼|COF216.53-3.02 (-1.38%) ▼|COP136.05+1.76 (+1.31%) ▲|COST911.37-4.38 (-0.48%) ▼|CRM251.78-7.52 (-2.90%) ▼|CSCO109.01-0.19 (-0.17%) ▼|CVS95.50-1.25 (-1.29%) ▼|CVX211.96+3.43 (+1.64%) ▲|DE687.04-6.64 (-0.96%) ▼|DHR205.38-2.24 (-1.08%) ▼|DIS104.81-0.48 (-0.46%) ▼|DUK120.54+0.32 (+0.26%) ▲|EMR152.72-0.08 (-0.05%) ▼|FDX320.49-1.88 (-0.58%) ▼|GD359.99+0.60 (+0.17%) ▲|GE335.79-1.24 (-0.37%) ▼|GEV947.49+5.57 (+0.59%) ▲|GILD146.58-4.42 (-2.92%) ▼|GM87.23-0.51 (-0.58%) ▼|GOOG332.40-2.92 (-0.87%) ▼|GOOGL335.77-2.69 (-0.79%) ▼|GS1,033.62-4.68 (-0.45%) ▼|HD320.32-0.68 (-0.21%) ▼|HON208.32-1.29 (-0.62%) ▼|IBM231.56-3.28 (-1.40%) ▼|INTC101.68+5.88 (+6.14%) ▲|INTU321.32-11.38 (-3.42%) ▼|ISRG358.51-8.19 (-2.23%) ▼|JNJ268.32-6.83 (-2.48%) ▼|JPM357.00-1.62 (-0.45%) ▼|KO88.24+0.17 (+0.19%) ▲|LIN472.33-5.25 (-1.10%) ▼|LLY1,116.00-32.74 (-2.85%) ▼|LMT536.40+11.24 (+2.14%) ▲|LOW204.33-0.24 (-0.12%) ▼|LRCX316.43+8.78 (+2.85%) ▲|MA570.32-8.85 (-1.53%) ▼|MCD255.15-0.57 (-0.22%) ▼|MDLZ61.37+0.09 (+0.15%) ▲|MDT92.35-1.81 (-1.92%) ▼|META617.88+1.11 (+0.18%) ▲|MMM168.03-0.48 (-0.28%) ▼|MO68.94+0.07 (+0.10%) ▲|MRK146.57-3.76 (-2.50%) ▼|MS217.40-0.31 (-0.14%) ▼|MSFT494.03-5.67 (-1.13%) ▼|MU1,016.88+0.29 (+0.03%) ▲|NEE83.64+0.22 (+0.26%) ▲|NFLX76.53-1.73 (-2.20%) ▼|NKE38.47+0.06 (+0.14%) ▲|NOW135.36-5.91 (-4.18%) ▼|NVDA232.54+2.18 (+0.95%) ▲|ORCL169.32+10.49 (+6.60%) ▲|PEP138.17+0.54 (+0.39%) ▲|PFE27.80-0.65 (-2.27%) ▼|PG145.43-1.02 (-0.70%) ▼|PLTR174.60+0.27 (+0.15%) ▲|PM185.36+2.85 (+1.56%) ▲|QCOM179.87+11.13 (+6.59%) ▲|RTX200.79-1.34 (-0.66%) ▼|SBUX104.47-1.35 (-1.28%) ▼|SCHW109.29-1.09 (-0.99%) ▼|SO88.11-0.66 (-0.74%) ▼|SPG209.44-2.08 (-0.98%) ▼|T25.68-0.51 (-1.95%) ▼|TMO606.80-6.95 (-1.13%) ▼|TMUS182.45+0.93 (+0.51%) ▲|TSLA361.55+7.47 (+2.11%) ▲|TXN258.44+4.61 (+1.82%) ▲|UBER75.76-0.20 (-0.26%) ▼|UNH397.14-3.80 (-0.95%) ▼|UNP289.62+0.47 (+0.16%) ▲|UPS102.29-1.21 (-1.17%) ▼|USB63.37-0.16 (-0.25%) ▼|V375.07-3.68 (-0.97%) ▼|VZ50.14-0.45 (-0.89%) ▼|WFC89.97+0.78 (+0.87%) ▲|WMT107.14-1.28 (-1.18%) ▼|XOM159.47-2.74 (-1.69%) ▼|
20 C
New York
Tuesday, September 8, 2026

Tag: support

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.1 The results showed that TALVEY® (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72.0%, and clinically meaningful reduction of up to 53.0% in the risk of death, compared to the standard regimen of daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM).1 Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months.1  

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

EpiCooler Product Information Updated As Consumer Interest In Portable AC Grows In 2026

Kaunas, Lithuania, June 13, 2026 (GLOBE NEWSWIRE) --

An informational overview examining EpiCooler Portable AC Product Details, Publicly available product disclosures and what consumers often consider when researching portable cooling devices in 2026

AESC and Prevalon Energy Sign 10+ GWh Strategic Supply Agreement to Support Global Energy Storage Growth

SHANGHAI, June 13, 2026 /PRNewswire/ -- AESC, a global leader in high-performance batteries and energy storage systems, and Prevalon Energy, a Mitsubishi Power Americas...

AESC and Prevalon Energy Sign 10+ GWh Strategic Supply Agreement to Support Global Energy Storage Growth

SHANGHAI, June 13, 2026 /CNW/ -- AESC, a global leader in high-performance batteries and energy storage systems, and Prevalon Energy, a Mitsubishi Power Americas...

Huawei Cloud Becomes Thailand’s First with Government-Recognized HCCDX Certification Program

BANGKOK, June 13, 2026 /PRNewswire/ -- Huawei Cloud Thailand has officially received a recognition for its HUAWEI CLOUD Developer Certification (HCCDX) from Thailand Professional...

No Deposit Bonus Casino Real Money 2026 – BetOnline Offered No Deposit Bonuses

BetOnline issues a USA press announcement focused on No Deposit Casino interest, highlighting casino access, promotional visibility, player support, and responsible participation.
BetOnline issues a USA press announcement focused on No Deposit Casino interest, highlighting casino access, promotional visibility, player support, and responsible participation.

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type...

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. Tinlarebant is an investigational, once-daily oral therapy for the treatment of Stargardt disease type 1 (STGD1), a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss. STGD1 affects an estimated 53,000 people in the U.S. alone, and there are currently no approved treatment options for the disease.

The U.S. Government Just Took a 10% Stake in a Mining Company. Why and Who’s Next?

Washington is now buying pieces of American miners. A former Pentagon advisor explains what it could mean and his latest prediction.
Washington is now buying pieces of American miners. A former Pentagon advisor explains what it could mean and his latest prediction.

Government of Canada supports the 37th Francos de Montréal

Les Francos de Montréal receive support from the Government of Canada.MONTRÉAL, June 12, 2026 /CNW/ - The Francophonie is a pillar of our collective...

HorseWood Claims Evaluated: The Horse Gelatin Trick for Natural Male Enhancement Support

Horsewood supplement evaluated: 7-herb botanical male vitality formula, NCCIH research context, and 60-day money-back guarantee.

SpaceX IPO Project Unlimited (Weiss Ratings’ Michael Robinson Disruptors & Dominators Newsletter) Elon’s Trillion Dollar Plan to Save AI

SPCX IPO live: Weiss Ratings' Disruptors & Dominators covers orbital AI supply chain research. 4 bonus reports. Weiss Ratings LLC.

OpenText to Create 400 Jobs with €105 Million Investment in Cork and Galway to Expand Agentic AI and Sovereign Cloud in Europe

Taoiseach Micheál Martin TD and CEO of IDA Ireland Michael Lohan join OpenText to announce new Cork Centre of Excellence for EMEA Investment marks...

OpenText to Create 400 Jobs with €105 Million Investment in Cork and Galway to Expand Agentic AI and Sovereign Cloud in Europe

Taoiseach Micheál Martin TD and CEO of IDA Ireland Michael Lohan join OpenText to announce new Cork Centre of Excellence for EMEA Investment marks...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSupport